Closely-held PharmaJet’s needle-free injection system will be used to deliver Diomics’ Diocheck SARS-CoV-2 visual immune response indicator.
Diomics’ immune response indicator will be injected under the skin using PharmaJet’s Tropis needle-free injection device. The indicator consists of a COVID-19 antigen-containing biopolymer, which causes a skin reaction in individuals who have been exposed to SARS-CoV-2.
In a statement, Chris Cappello, PharmaJet’s president and CEO, said, “Our needle-free design features a precise and consistent method of delivery to ensure accuracy, in addition to its proven ease of administration in mass immunization campaigns.”
